Details for New Drug Application (NDA): 214688
✉ Email this page to a colleague
NDA 214688 describes CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, which is a drug marketed by Glenmark Pharms Ltd, Chartwell Rx, Padagis Israel, Cosette, and Taro, and is included in five NDAs. It is available from five suppliers. Additional details are available on the CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE profile page.
The generic ingredient in CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.
The generic ingredient in CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.
Summary for 214688
| Tradename: | CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE |
| Applicant: | Glenmark Pharms Ltd |
| Ingredient: | betamethasone dipropionate; calcipotriene |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, FOAM;TOPICAL | Strength | 0.064%;0.005% | ||||
| Approval Date: | Mar 21, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
